Growth patterns of patients with Noonan syndrome: correlation with age and genotype
- 1 May 2016
- journal article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 174 (5) , 641-650
Abstract
Background: Growth patterns of patients with Noonan syndrome (NS) were established before the involved genes were identified.Objective: The goal of this study was to compare growth parameters according to genotype in patients with NS.Subjects and methods: The study population included 420 patients (176 females and 244 males) harboring mutations in thePTPN11,SOS1,RAF1, orKRASgenes. NS-associatedPTPN11mutations (NS-PTPN11) and NS with multiple lentigines-associatedPTPN11mutations (NSML-PTPN11) were distinguished. Birth measures and height and body mass index (BMI) measures at 2, 5, 10 years, and adulthood were compared with the general population and between genotypes.Results: Patients with NS were shorter at birth (mean birth length standard deviation score (SDS): –1.0 ± 1.4;P< 0.001) and throughout childhood than the healthy population, with height SDS being –2.1 ± 1.3 at 2 years, and –2.1 ± 1.2 at 5 and 10 years and adulthood (P< 0.001). At birth, patients withNS-PTPN11were significantly shorter and thinner than patients withNSML-PTPN11,SOS1, orKRAS. Growth retardation was significantly less severe and less frequent at 2 years in patients withNSML-PTPN11andSOS1than in patients withNS-PTPN11(P< 0.001 andP= 0.002 respectively). Patients with NS had lower BMI at 10 years (P< 0.001). No difference between genotypes was demonstrated.Conclusion: Determining the growth patterns of patients with NS according to genotype should better inform clinicians about the natural course of growth in NS so that they can optimize the follow-up and management of these patients.Keywords
This publication has 34 references indexed in Scilit:
- Noonan syndrome-causing SHP2 mutants inhibit insulin-like growth factor 1 release via growth hormone-induced ERK hyperactivation, which contributes to short statureProceedings of the National Academy of Sciences, 2012
- A Mosaic Activating Mutation inAKT1Associated with the Proteus SyndromeNew England Journal of Medicine, 2011
- Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome–associated PTPN11 mutationJournal of Clinical Investigation, 2011
- MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1L613V mutationJournal of Clinical Investigation, 2011
- Noonan syndrome and clinically related disordersBest Practice & Research Clinical Endocrinology & Metabolism, 2011
- Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutationJournal of Clinical Investigation, 2010
- Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β SignalingMolecular and Cellular Biology, 2010
- Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformationProceedings of the National Academy of Sciences, 2009
- Role of ERK1/2 signaling in congenital valve malformations in Noonan syndromeProceedings of the National Academy of Sciences, 2008
- Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndromeJournal of Clinical Investigation, 2007